Digital Marketing

Week ending August 16, 2026

1. Content opportunities this week

1. “For Cosentyx dosing in plaque psoriasis, what loading regimen and maintenance dose should I follow?”
   Six answers disagree on whether loading is four or five weekly doses. A single label-aligned dosing page would resolve a high-value factual gap.

2. “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?”
   Answers are lengthy but generic and repeatedly hedge toward device-specific instructions. A structured pen/syringe/storage guide could become the definitive citable source.

3. “What IL-17 role does Cosentyx target, and how is that commonly described compared with other psoriasis medicines?”
   Responses are unusually short—71–126 words—and use broad language such as “more targeted.” A clear mechanism explainer comparing IL-17A, TNF-α, IL-12/23 and IL-23 pathways would fill a thin-answer gap.

4. “Patients keep asking whether Cosentyx is ‘stronger’ than Enbrel (etanercept). What would be a neutral way to frame that comparison?”
   Answers are short (111–189 words), repeatedly address “stronger/weaker” without a detailed evidence framework, and Enbrel appears in all six responses.

5. “Can Cosentyx be used during pregnancy or breastfeeding, and what guidance does the label give about live vaccines for infants exposed in utero or via lactation?”
   This recurring safety question has inconsistent treatment of contraindication language and infant live-vaccine guidance, despite six responses.

2. Where competitors may be winning visibility

• Taltz: 10 mentions, the highest total. It appears in all six responses to the Cosentyx-versus-Taltz nurse question and in switching discussions. Prioritize a neutral, evidence- and label-based comparison covering dosing, indications, comorbidities, tolerability and access.
• Humira: 9 mentions, concentrated in the plaque-psoriasis question about effectiveness and side effects (six responses). This is a direct visibility opportunity for a comprehensive Cosentyx-versus-Humira explainer.
• Stelara: 9 mentions, concentrated in the practical-differences question (six responses). Build a comparison covering mechanism, dosing, approved uses and safety considerations without implying universal superiority.
• Enbrel: 8 mentions, especially the “stronger” question, where competitor visibility is strongest relative to answer length.

3. Topics worth resolving with authoritative content

• Plaque-psoriasis dosing: explicitly reconcile four-versus-five-dose loading descriptions, maintenance timing, strengths and indication-specific variations.
• Boxed warnings and infection risk: answers conflict on whether Cosentyx has a U.S. boxed warning. Create a label-referenced page distinguishing boxed warnings from major warnings, infection precautions, TB screening and IBD considerations.
• Pregnancy, lactation and infant live vaccines: define what the label says, what is unknown, and how exposure timing affects clinician discussion—without converting “limited data” into a blanket contraindication.

4. Prioritization — recurring vs. one-off

The question count is stable at 20 each week, while response volume fell to 120 from 140. Safety themes are clearly recurring: infection risk, hedging, IBD, contraindications, dosing, pregnancy/lactation and pediatric use appear across the rolling history. Kidney/hepatic impairment is also recurring across three of four weeks. Competitor comparisons recur across weeks, led by Taltz, Humira, Stelara and Enbrel. No topic should be treated as definitively first-time from this aggregate dataset alone.

5. Recommended content actions

1. Publish the authoritative plaque-psoriasis dosing page—highest urgency because six answers conflict.
2. Create the pen/syringe/storage administration hub—addresses a repeated practical question and reduces generic hedging.
3. Publish the boxed-warning/infection-risk explainer—recurring, high-safety-volume topic with direct factual inconsistency.
4. Build a neutral Cosentyx comparison series, starting with Taltz, then Humira/Stelara—competitors appear 10, 9 and 9 times respectively.
5. Add IL-17A and Enbrel “stronger” explainers—short AI answers indicate thin source material, with Enbrel appearing eight times.